Skin Cancer/Melanoma

Underlying mechanism for increased risk now defined.

Melanoma is on the rise in children and teenagers.

Rajni Kannan discusses the importance patient education or managing the side effects associated ipilimumab and vemurafenib in metastatic melanoma.

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.

Researchers find that people who took NSAIDs were less likely to develop skin cancer.

Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.

After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.

As an immunotherapy, Yervoy presents a unique set of side effects and it was approved along with a Risk Evaluation and Mitigation Strategy to address these events.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Sun exposure to usually-covered skin is yet another risk for skin cancer.

Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate

Useful Online Resources and Clinical Trials for Melanoma

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.